2008
DOI: 10.1167/iovs.07-1012
|View full text |Cite
|
Sign up to set email alerts
|

Tauroursodeoxycholic Acid Preservation of Photoreceptor Structure and Function in therd10Mouse through Postnatal Day 30

Abstract: TUDCA is efficacious and safe in preserving vision in the rd10 mouse model of RP when treated between P6 and P30. At P30, a developmental stage at which nearly all rods are absent in the rd10 mouse model of RP, TUDCA treatment preserved rod and cone function and greatly preserved overall photoreceptor numbers.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
89
1
2

Year Published

2008
2008
2019
2019

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 84 publications
(95 citation statements)
references
References 38 publications
3
89
1
2
Order By: Relevance
“…Impressively, it has been recently shown that TUDCA preserves photoreceptor structure and function in the rd10 retinitis pigmentosa mouse model through postnatal day 30 ( 134 ). TUDCA was able to preserve rods and cones through postnatal day 30, the stage at which photoreceptor cell loss peaks.…”
Section: Discussionmentioning
confidence: 98%
“…Impressively, it has been recently shown that TUDCA preserves photoreceptor structure and function in the rd10 retinitis pigmentosa mouse model through postnatal day 30 ( 134 ). TUDCA was able to preserve rods and cones through postnatal day 30, the stage at which photoreceptor cell loss peaks.…”
Section: Discussionmentioning
confidence: 98%
“…However, in models in which degeneration progresses more slowly than in the rd10 mouse, greater sprouting of cell processes is observed, mainly from bipolar or horizontal cells (Claes et al, 2004;Cuenca et al, 2004;Haverkamp et al, 2006), which may difficult the complete recovery of the normal retina structure even if the therapy were effective. In addition to these arguments, the rd10 model of retinal degeneration has recently been used with success to test the effects of different therapeutic approaches (Otani et al, 2004;Rex et al, 2004;Boatright et al, 2006;Komeima et al, 2007;Phillips et al, 2008).…”
Section: Discussionmentioning
confidence: 99%
“…Synthetic TUDCA has been shown to exhibit antiapoptotic properties in neurodegenerative diseases, including those affecting the retina. Systemic administration of TUDCA has been demonstrated to slow retinal degeneration in both the rd10 autosomal recessive RP mouse model (Boatright et al, 2006;Drack et al, 2012;Oveson et al, 2011;Phillips et al, 2008) and in a LIRD mouse model (Boatright et al, 2006;Oveson et al, 2011). In these two retinal degeneration models, TUDCA-treated animals were shown to maintain better visual function, thicker ONL and better preservation of outer segments than untreated animals.…”
Section: Tauroursodeoxycholic Acid (Tudca)mentioning
confidence: 99%